WallStSmart

Baxter International Inc (BAX)vsBecton Dickinson and Company (BDX)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Becton Dickinson and Company generates 96% more annual revenue ($22.48B vs $11.47B). BDX leads profitability with a 4.2% profit margin vs -9.3%. BDX appears more attractively valued with a PEG of 1.11. BAX earns a higher WallStSmart Score of 54/100 (C-).

BAX

Buy

54

out of 100

Grade: C-

Growth: 6.7Profit: 3.5Value: 5.7Quality: 5.5
Piotroski: 4/9Altman Z: 1.98

BDX

Buy

52

out of 100

Grade: C-

Growth: 4.0Profit: 5.5Value: 5.3Quality: 5.0
Piotroski: 6/9Altman Z: 1.49
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BAXUndervalued (+51.0%)

Margin of Safety

+51.0%

Fair Value

$45.43

Current Price

$23.37

$22.06 discount

UndervaluedFair: $45.43Overvalued
BDXUndervalued (+11.0%)

Margin of Safety

+11.0%

Fair Value

$202.87

Current Price

$183.82

$19.05 discount

UndervaluedFair: $202.87Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BAX2 strengths · Avg: 8.0/10
Price/BookValuation
1.9x8/10

Reasonable price relative to book value

EPS GrowthGrowth
36.8%8/10

Earnings expanding 36.8% YoY

BDX1 strengths · Avg: 8.0/10
Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Areas to Watch

BAX4 concerns · Avg: 2.8/10
Altman Z-ScoreHealth
1.984/10

Grey zone — moderate risk

Debt/EquityHealth
1.563/10

Elevated debt levels

PEG RatioValuation
36.682/10

Expensive relative to growth rate

Return on EquityProfitability
-17.1%2/10

ROE of -17.1% — below average capital efficiency

BDX4 concerns · Avg: 3.0/10
P/E RatioValuation
31.6x4/10

Premium valuation, high expectations priced in

Return on EquityProfitability
3.9%3/10

ROE of 3.9% — below average capital efficiency

Profit MarginProfitability
4.2%3/10

4.2% margin — thin

EPS GrowthGrowth
-31.4%2/10

Earnings declined 31.4%

Comparative Analysis Report

WallStSmart Research

Bull Case : BAX

The strongest argument for BAX centers on Price/Book, EPS Growth.

Bull Case : BDX

The strongest argument for BDX centers on Price/Book. PEG of 1.11 suggests the stock is reasonably priced for its growth.

Bear Case : BAX

The primary concerns for BAX are Altman Z-Score, Debt/Equity, PEG Ratio. Debt-to-equity of 1.56 is elevated, increasing financial risk.

Bear Case : BDX

The primary concerns for BDX are P/E Ratio, Return on Equity, Profit Margin. Thin 4.2% margins leave little buffer for downturns.

Key Dynamics to Monitor

BAX profiles as a turnaround stock while BDX is a value play — different risk/reward profiles.

BAX carries more volatility with a beta of 0.59 — expect wider price swings.

BDX is growing revenue faster at 5.4% — sustainability is the question.

BDX generates stronger free cash flow (509M), providing more financial flexibility.

Bottom Line

BAX scores higher overall (54/100 vs 52/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Baxter International Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Baxter International Inc. is an American multinational health care company with headquarters in Deerfield, Illinois. The company primarily focuses on products to treat hemophilia, kidney disease, immune disorders and other chronic and acute medical conditions.

Visit Website →

Becton Dickinson and Company

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.

Visit Website →

Want to dig deeper into these stocks?